NASDAQ · Biotechnology

Lexicon Pharmaceuticals, Inc. (LXRX) Stock

$1.68 -4.55% NASDAQ: LXRX Healthcare

Valuation

MetricValue
Price$1.68
Market Cap$746.25M
P/E Ratio-12.10
P/B Ratio4.56
P/S Ratio19.49
EPS (TTM)$-0.14
52-Week High$2.68
52-Week Low$1.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-40.40%
ROA-24.44%
ROCE-23.16%
Gross Margin-98.00%
Operating Margin-98.00%
Net Margin-147.38%
Debt/Equity0.34
Current Ratio4.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$31.0M$50.0M
Operating Profit$-87.0M$-101.0M$-172.0M$-197.0M$-49.0M
Net Profit$-88.0M$-102.0M$-177.0M$-200.0M$-50.0M
EPS$-0.61$-0.62$-0.80$-0.63$-0.14
Op Margin-29224.8%-72489.2%-14265.0%-634.2%-98.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$137.0M$194.0M$229.0M$298.0M$185.0M
Total Liabilities$23.0M$77.0M$136.0M$152.0M$77.0M
Cash$64.0M$46.0M$22.0M$67.0M$34.0M
Borrowings$2.0M$55.0M$106.0M$108.0M$62.0M

Latest News

Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion Insider Monkey · Jul 3, 2026 Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? Insider Monkey · Jun 11, 2026 Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? Motley Fool · Jun 11, 2026 How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates Simply Wall St. · Jun 4, 2026 Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions GlobeNewswire · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-87.0M$-89.0M$-162.0M$-179.0M$-68.0M
Investing Cash Flow$1.0M$-72.0M$-50.0M$-16.0M$113.0M
Financing Cash Flow$-3.0M$93.0M$-1.0M$-3.0M$-1.0M
Net Cash Flow$-62.0M$-18.0M$-24.0M$44.0M$-3.0M
Free Cash Flow$-88.0M$-90.0M$-162.0M$-180.0M$-68.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.10
EV / EBITDA-15.82
FCF Yield-9.86%
Quick Ratio13.29
Interest Coverage-6.50
Return 1Y90.08%
Return 3Y15.00%
Return 5Y-42.55%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCRXBioCryst Pharmaceuticals, Inc. $8.57 +3.44% -5.84 $2.18B 0.00%
DMACDiaMedica Therapeutics Inc. $8.16 +1.88% -11.43 $439.70M 0.00%
IONSIonis Pharmaceuticals, Inc. $45.28 +4.57% -12.57 $7.52B 0.00%
MNKDMannKind Corporation $3.29 -3.95% -24.73 $1.05B 0.00%
NMRANeumora Therapeutics, Inc. $0.49 +1.42% -0.41 $90.16M 0.00%

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is led by CEO Michael S. Exton, employs 103 people, headquartered in US, publicly traded since 2000.

Lexicon Pharmaceuticals, Inc. (LXRX) stock trades at $1.68 with a market capitalization of $746.25M. The stock is valued at a price-to-earnings (P/E) ratio of -12.10, price-to-book of 4.56, price-to-sales of 19.49. Over the past 52 weeks the stock has ranged between $1.10 and $2.68, and currently trades 37.3% below its 52-week high.

On profitability, Lexicon Pharmaceuticals, Inc. generates a return on equity (ROE) of -40.40%, return on capital employed of -23.16%, an operating margin of -98.00%, a net profit margin of -147.38%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides